About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNANCT05101161

Neurofeedback Using Implanted Deep Brain Stimulation Electrodes

Deep brain stimulation (DBS) has become a gold-standard symptomatic treatment option for Parkinson's disease (PD) and is also explored for a variety of other neurological disorders. The implantation o...

Lead sponsor: ETH Zurich•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Oliver Bichsel, MD, MSc ETH

CONTACT

+41 44 510 72 34 oliver.bichsel@hest.ethz.ch

Sponsors

Lead Sponsor

ETH Zurich

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•patients undergoing clinically indicated implantation of a Percept™ PC neurostimulator, age ≥ 18 years as well as planned hospitalisation of ≥ 3 days after operation

Exclusion Criteria

•minimal prognosticated survival of less than 1 year, reduced state of consciousness (i. e. Glasgow Coma Scale \< 15), inability to communicate (in terms of hearing, seeing, speaking and understanding), other significant concomitant diseases (e. g. cardiovascular disease, infectious disease, isolation), inability to follow procedures, insufficient knowledge of project language, inability to give consent and unlikeliness to follow protocol.

Related studies

EMBRACE Tremor BiFUS

NCT06974916 · Essential Tremor

Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

NCT06553625 · Parkinson Disease, Dystonia, and more

Safety and Tolerability of Patterned Stimulation for DBS in the Home Setting

NCT07410598 · Parkinson Disease, Deep Brain Stimulation

RECRUITINGPhase 1

Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy

NCT02531880 · Epilepsy

Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD

NCT07187843 · Parkinson Disease, Parkinsonian Disorders, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 27, 2025Terms

Trial snapshot

StatusRECRUITING

PhaseNA

Enrollment50

Start dateSep 2021

Last updatedFeb 27, 2025

Condition

Parkinson Disease Epilepsy Essential Tremor

Locations shown

ETH Zurich

Zurich, Canton of Zurich

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 27, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions